Latest News in the pharma Industry

Research & Development

Merck announces results from Phase III studies of Zepatier in chronic hepatitis C patient populations

Merck announces results from Phase III studies of Zepatier in chronic hepatitis C patient populations

17 Apr 2016

Data from these additional Phase III studies were presented at The International Liver Congress 2016.

Read more 
Shire Submits NDA to FDA for new formulation of Vyvanse CII as chewable tablets

Shire Submits NDA to FDA for new formulation of Vyvanse CII as chewable tablets

15 Apr 2016

New formulation, in adherence with approved indications, intended for children, adolescents and adults with difficulty swallowing or opening capsules.

Read more 
Presage Biosciences extends research collaboration with Takeda to discover novel cancer drug combinations

Presage Biosciences extends research collaboration with Takeda to discover novel cancer drug combinations

14 Apr 2016

The agreement provides Takeda access to Presage’s proprietary CIVO technology platform to enable identification of novel oncology drug combinations in solid tumours.

Read more 
AmpliPhi Biosciences terminates collaboration agreement with Intrexon

AmpliPhi Biosciences terminates collaboration agreement with Intrexon

14 Apr 2016

Terminating the EEC allows AmpliPhi to take advantage of the rapid advancements being made in the field of synthetic biology.

Read more 
Arena Pharmaceuticals reports favorable results from Phase Ib multiple-ascending dose clinical trial of APD371

Arena Pharmaceuticals reports favorable results from Phase Ib multiple-ascending dose clinical trial of APD371

14 Apr 2016

APD371 is a highly selective and potent agonist of the cannabinoid 2 receptor with potential utility in the treatment of pain.

Read more 
AbbVie receives FDA accelerated approval of Venclexta (venetoclax) tablets

AbbVie receives FDA accelerated approval of Venclexta (venetoclax) tablets

13 Apr 2016

The first BCL-2 inhibitor in relapsed/refractory chronic lymphocytic leukemia patients with 17p deletion.

Read more 
PhotoPharmics announces new discovery may have a major impact on treating Parkinson’s disease through the eyes

PhotoPharmics announces new discovery may have a major impact on treating Parkinson’s disease through the eyes

12 Apr 2016

Recent discoveries about the eye’s involvement in Parkinson’s offer new hope to the millions of people who suffer from the disease.

Read more 
Despite its weak pipeline, schizophrenia market may benefit from drugs used in similar indications

Despite its weak pipeline, schizophrenia market may benefit from drugs used in similar indications

12 Apr 2016

Read more 
Pooled analysis from seven clinical studies demonstrates consistent efficacy for ceftazidime-avibactam in the treatment of multi-drug resistant Gram-negative bacteria

Pooled analysis from seven clinical studies demonstrates consistent efficacy for ceftazidime-avibactam in the treatment of multi-drug resistant Gram-negative bacteria

11 Apr 2016

Encouraging new data relevant to escalating Gram-negative infection crisis presented at 26th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID).

Read more 
Allergan and Heptares announce global R&D and commercialization partnership for novel treatments in Alzheimer's and other neurological disorders

Allergan and Heptares announce global R&D and commercialization partnership for novel treatments in Alzheimer's and other neurological disorders

10 Apr 2016

Adds selective muscarinic agonists discovered and developed by Heptares to Allergan's leading CNS pipeline.

Read more 
Eli Lilly and AstraZeneca announce continuation of pivotal clinical trial for people with early Alzheimer's disease

Eli Lilly and AstraZeneca announce continuation of pivotal clinical trial for people with early Alzheimer's disease

8 Apr 2016

Phase II/III trial of AZD3293, an oral potent small molecule BACE inhibitor, will continue to Phase III after positive interim safety data.

Read more 
Cambridge, UK, workshop to discuss accelerated preclinical drug development and readying molecules for Phase I

Cambridge, UK, workshop to discuss accelerated preclinical drug development and readying molecules for Phase I

7 Apr 2016

The event content will include API and formulation development, clinical study design and regulatory requirements.

Read more